- Home
- NAAS vs ELOX Comparison
NAAS vs ELOX Comparison
Compare NAAS & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAAS | ELOX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 43.8M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAAS | ELOX |
|---|---|---|
| Price | $3.27 | $11.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.9K | ★ 42.4K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $10.00 |
| 52 Week High | $4.54 | $15.00 |
Technical Indicators
Market Signals| Indicator | NAAS | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 43.01 |
| Support Level | $2.85 | $10.51 |
| Resistance Level | $3.25 | $14.50 |
| Average True Range (ATR) | 0.26 | 2.18 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 39.47 | 32.74 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.